These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10851473)

  • 1. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Cencioni S; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):257-64. PubMed ID: 10851473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T; Canossi A; Di Rocco M; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):373-83. PubMed ID: 10851498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back.
    Berghella AM; Pellegrini P; Del Beato T; Marini M; Tomei E; Adorno D; Casciani CU
    Cancer Immunol Immunother; 1998 Jan; 45(5):241-9. PubMed ID: 9439647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
    Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU
    Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of immunological evaluation in colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Maccarone D; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):355-61. PubMed ID: 10851496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
    Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
    Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease stage prognostic indices in the early clinical screening of colorectal cancer patients.
    Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Casciani CU; Adorno D
    Cancer Biother Radiopharm; 1998 Apr; 13(2):89-98. PubMed ID: 10850345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological directives for biotherapy improvement in the treatment of colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Apr; 11(2):113-8. PubMed ID: 10851527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer.
    Pellegrini P; Contasta I; Berghella AM; Gargano E; Mammarella C; Adorno D
    Cancer Immunol Immunother; 2000 Sep; 49(7):388-94. PubMed ID: 10999465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of colorectal cancer upon host peripheral immune cell function.
    Evans CF; Galustian C; Bodman-Smith M; Dalgleish AG; Kumar D
    Colorectal Dis; 2010 Jun; 12(6):561-9. PubMed ID: 19250260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Native soluble carcinoembryonic antigen is not involved in the impaired activity of CD56 natural killer cells in malignant pleural effusion.
    Qi J; Li D; Feng J; Yang S; Su Y; Fang M; Tan Z; Shi H; Yan X; Gong F; Zheng F
    Respiration; 2013; 86(3):216-23. PubMed ID: 23258197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T ; Canossi A; Maccarone D; Papola F; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Dec; 12(6):385-93. PubMed ID: 10851492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CEA, CA-19-9 and il-8, sTNFRII and sil-2R in persons at high risk of colorectal cancer].
    Grotowski M; Wojtuń S
    Pol Merkur Lekarski; 2003 Apr; 14(82):327-30. PubMed ID: 12868194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J; Broxmeyer HE
    Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoresponsiveness of cancer patients: effect of blood transfusion and immune reactivity of tumor infiltrating lymphocytes.
    Quintiliani L; Iudicone P; Di Girolamo M; Buzzonetti A; Guglielmetti M; Lapponi P; Traietti P; Monno D; Giuliani E
    Cancer Detect Prev; 1995; 19(6):518-26. PubMed ID: 8925521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput assay of NK cell activity in whole blood and its clinical application.
    Lee SB; Cha J; Kim IK; Yoon JC; Lee HJ; Park SW; Cho S; Youn DY; Lee H; Lee CH; Lee JM; Lee KY; Kim J
    Biochem Biophys Res Commun; 2014 Mar; 445(3):584-90. PubMed ID: 24561245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.